The identified L-asparaginases exhibited favorable biochemical properties, potent and selective anti-leukemic activity, and enhanced safety profiles, position these gut microbiome-derived enzymes as promising biotherapeutic scaffolds for next-generation leukemia treatment, pending further optimization of substrate affinity to meet clinical standards.
Abstract
L-asparaginase is essential for acute lymphoblastic leukemia treatment; however, current Escherichia coli and Erwinia chrysanthemi formulations face significant limitations, including immunogenicity, glutaminase-associated toxicity, and short plasma half-life. The human gut microbiome represents an unexplored reservoir of therapeutic enzymes that may offer superior biocompatibility due to host-commensal co-evolution. We employed a systematic genome-mining approach to screen human gut metagenomic data for novel L-asparaginase candidates. Five candidate enzymes from the genera Bacteroides, Ruminococcus, Clostridium, and Prevotella were identified using virtual screening. These enzymes were subsequently codon-optimized and heterologously expressed in E. coli, thereby validating our computational selection strategy. Biochemical characterization revealed optimal activity at alkaline pH (8.0-9.0), robust performance at physiological temperature (37 °C), and excellent storage stability. Ruminococcus_seq7 exhibited exceptional kinetic properties (Km = 0.53 ± 0.19 mM; Vmax = 78.6 ± 5.59 U/mg), whereas Bacteroides_seq104 showed intermediate kinetics (Km = 2.04 ± 0.57 mM; Vmax = 75.4 ± 5.75 U/mg). These lead candidates demonstrated complementary anti-leukemic profiles: Ruminococcus_seq7 showed broad-spectrum activity against T-cell leukemias (IC₅₀: 5.1-8.6 U/mL for Jurkat, MOLT-4, and THP-1), while Bacteroides_seq104 exhibited remarkable potency against THP-1 cells (IC₅₀ = 0.9 U/mL) and successfully overcame resistance in REH cells (IC₅₀ = 36.9 U/mL). Both enzymes maintained >95% viability in healthy HUVEC cells. This study provides proof-of-concept for the discovery of therapeutic enzyme from the human gut microbiome. The identified L-asparaginases exhibited favorable biochemical properties, potent and selective anti-leukemic activity, and enhanced safety profiles. The absence of glutaminase activity and high biocompatibility position these gut microbiome-derived enzymes as promising biotherapeutic scaffolds for next-generation leukemia treatment, pending further optimization of substrate affinity to meet clinical standards.
Heat-killed DX2034 significantly reduced lipid accumulation, intracellular triglyceride content, and expression of adipogenesis-related genes, including C/EBPα, PPARγ, FABP4, LPL, and FASN, supporting its potential as a functional probiotic or postbiotic candidate.
Do-Young Park, Ji Hyung Kim, Do-Young Park· Letters in Applied Microbiol...· 0 citations
A comprehensive probiogenomic analysis of Weissella paramesenteroides UFTM 2.6.1 isolated from unpasteurized cow's milk from the Triângulo Mineiro region highlights its probiotic potential through in vitro and in silico analyses and investigates biotechnological prospects.
The novel Lacticaseibacillus isolate seamlessly combines absolute biosecurity clearance and superior genomic resistance to industrial mutational drift with premium targeted antimicrobial and prebiotic assimilation profiles to establish the isolate as a highly secure, predictable, and elite raw material for next-generat...
H. Kurt· Fabad journal of pharmaceuti...· 0 citations
Spore-forming Bacillus probiotics are widely used in aquaculture, but host-associated strains from Siamese fighting fish (Betta splendens Regan) remain uncharacterized. Ten Bacillus isolates were recovered from the gastrointestinal tract of farmed B. splendens by heat selection and were identified by biochemical testin...
Vasana Jinatham, Kritsakorn Saninjuk, Benjarat Suwannawong et al.· The Scientist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.